BME · GRF.MC
Grifols, S.A.
€10.83+€0.15 (+1.41%)
Grifols, S.A.’s quoted price sits in the upper half of its reported 52-week range, 7.52% below the high.
Loading market information…
BME · FAE.MC · EUR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 08:13 AM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Faes Farma, S.A.’s quoted price sits in the lower half of its reported 52-week range, 11.86% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Faes Farma, S.A.’s forward annual dividend is €0.17 per share, paid semi-annual. The forward yield is 3.63% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Faes Farma, S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Faes Farma, S.A. is a pharmaceutical enterprise dedicated to the research, development, manufacture, and distribution of both finished medicinal products and crucial raw materials. Its extensive operations span Spain and a multitude of international markets. The company's comprehensive product line encompasses prescription drugs, generic alternatives, over-the-counter (OTC) remedies, nutritional supplements, infant formula, and various other health-related items. Among its diverse offerings are Actimag (a magnesium pidolate), the anti-allergic Bilaxten, the anti-infective Bronquidiazina CR, Claversal for ulcerative colitis and Crohn's disease, the corticoid Dezacor, the anti-inflammatory Dolotren (also available as Dolotren Gel), Dynamogen (an anti-anorexic), Ferroprotina (an anti-anaemic), Hidroferol, Lipofen, Positon for dermatological conditions, strength-enhancing products such as Potenciator and Surmenalit, the laxative Pruina, the muscle relaxant and analgesic Robaxisal Compuesto, Trausan (a citicoline-based product), the venous vasoprotector Venosmil (and Venosmil Gel), and the anti-influenza medication Yendol. Furthermore, Faes Farma provides key active pharmaceutical ingredients, including Bilastine (an antihistamine molecule for allergic rhinitis, conjunctivitis, and urticaria), Calcifediol for bone metabolism, Deflazacort for treating osteoarticular diseases, Hidrosmin for venous insufficiency, and Mesalazine for digestive problems. The firm also engages in significant export activities. Founded in 1933, Faes Farma, S.A. is headquartered in Leioa, Spain.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:44 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€10.83+€0.15 (+1.41%)
Grifols, S.A.’s quoted price sits in the upper half of its reported 52-week range, 7.52% below the high.
€61.85+€0.30 (+0.49%)
Laboratorios Farmaceuticos Rovi, S.A.’s quoted price sits in the lower half of its reported 52-week range, 28.66% below the high.
€10.60+€0.08 (+0.76%)
Almirall, S.A.’s quoted price sits in the lower half of its reported 52-week range, 24.18% below the high.
€68.50-€0.75 (-1.08%)
Pharma Mar, S.A.’s quoted price sits in the lower half of its reported 52-week range, 34.93% below the high.
€53.60-€0.20 (-0.37%)
Clínica Baviera, S.A.’s quoted price sits in the upper half of its reported 52-week range, 13.55% below the high.
€2.56-€0.01 (-0.39%)
Laboratorio Reig Jofre, S.A.’s quoted price sits in the lower half of its reported 52-week range, 24.71% below the high.
€2.51+€0.01 (+0.32%)
Oryzon Genomics S.A.’s quoted price sits in the lower half of its reported 52-week range, 33.17% below the high.
€2.64+€0.01 (+0.38%)
Atrys Health, S.A.’s quoted price sits in the lower half of its reported 52-week range, 21.19% below the high.
